Muc21 as a suitable candidate for immunotoxins development for targeting esophageal cancer

Elham Karimi,1,* Aliakbar haddad-mashadrizeh,2 Mohammad reza saberi,3

1. Department of Biology, Science and Research branch, Islamic Azad University, Khorasan Razavi, Neyshabur, Iran
2. Department of Biology, Faculty of Science and Cell and Molecular Biotechnology Research Group, Institute of Biotechnolog
3. Department of Medical Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran



Esophageal cancer is the world's eighth most common cancer and the sixth most common cause of cancer death in the world. in this regard, iran is the second country with the highest death rate due to this cancer in the eastern part of the middle east. in spite of multiple therapeutic approaches, treatment of this disease is one of the most difficult therapeutic challenges in oncology. however, immunotoxin drugs are promising way to targeting these types of cancer cells through detection corresponding specific antigens via ligands


In-silico expression assay ، protein atlas، string،


Bearing in mind, associated antigens of these cells were screened in this research to candidate the best antigen for immunotoxin development. our results led to a profile of antigens including dsg3, cisd1, muc21, ly6d, gpr171, il17ra, il1rapl2, il18r1, il15ra, cdcp1, cdkal1, ccr3, cisd1, dsc3, tmprss11d, tmprss11e, zdhhc7, dynap, clca2, dsg3, erbb2, fut3, slc10a6, c7orf60, c18orf32, btnl9, bcap29, aplf, ano2, adora3, ccr3, cd44, adora3 was developed. nonetheless, in-silico expression assay of these antigens reveal significance data, so that among them muc21 showed highest and widespread expression on the cells surface of skin, vagina, cervix and especially esophagus malignancy cells. on the other hand, corresponding ligands of this antigen based string investigation reveal a series of proteins that confirmed by molecular docking.


Taken together this study introducing muc21 as a good candidate for diagnosis as well as candidate for immunotoxin development for esophagus cancers.


Esophageal cancer, muc21, treatment, immunotoxins